Found Weight Loss Complaints and Alternatives: How to Compare Providers on Total Value
Compare on the twelve-month total, not the advertised monthly rate. Add the membership fee, the medication, any labs, and the number of billing cycles that fall inside a year. Most dissatisfaction with weight-loss telehealth traces back to a yearly figure nobody quoted at checkout, and pricing each line before signing removes almost all of that surprise.
Found Health, Inc. sits in a crowded field of subscription weight-care platforms. Its published materials are unusually detailed for the category, which makes it a useful worked example for how to price any competitor on the same basis.
Start with the annual figure, not the headline
Found’s plans and pricing page, checked in July 2026, advertises its GLP-1 program from $99 per month with insurance and $169 per month cash-pay. The footnote below those figures states that the pricing is based on twelve-month plans paid up front, and that monthly plans start at $199 per month with insurance and $289 per month cash-pay. The gap between the advertised number and the month-to-month number is roughly double.
A second detail changes the arithmetic again. Found’s offer terms describe plan pricing as billed every four weeks on a 28-day cycle. Thirteen 28-day cycles fit inside a calendar year, not twelve. That is disclosed in writing, and it is also the sort of thing a reader skims past, then notices later as an extra charge that seemed to arrive early.
Neither point is unique to one company. Prepaid annual discounts and four-week billing cycles are common across the category. They are simply easier to verify at Found than at platforms that publish less.
Three program shapes, and what each one leaves out
Almost every provider in this market fits one of a few structures. Knowing which one you are buying tells you where the uncovered costs will land.
| Program shape | What the recurring fee buys | Billed separately | Where the sticker misleads |
|---|---|---|---|
| Membership with compounded medication bundled | Clinical review, messaging, and the compounded drug | Labs where applicable, brand drugs | Price can move when the strength moves |
| Membership with brand medication billed separately | Prescribing and care coordination only | The entire drug cost | Fee looks low, drug cost dominates |
| Insurance-routed clinical care | Clinician access billed through a plan | Copay, coinsurance, deductible | Coverage decides the real number |
| Coaching-first, no prescribing | Behavioral program and tracking | Any medication, obtained elsewhere | Not comparable to a prescribing program |
| Cash-pay compounded, per-strength pricing | Supervision plus a stated drug price | Usually shipping tiers | Only fair if the higher strengths are quoted |
Found’s own offer terms describe three plans along these lines: a compounded GLP-1 plan, a generics plan covering oral non-GLP-1 medication, and a branded GLP-1 plan in which the medication is billed separately and may be filled through a pharmacy of the member’s choice or through the manufacturer self-pay channels. The terms also state that the plans are not available to people on government insurance including Medicare, Medicaid, TriCare and MediCal.
What the advertised outcome numbers rest on
Found’s home page leads with up to 15 to 20 percent weight loss with Wegovy and Zepbound, footnoted to a 68-week trial and a 72-week trial. Those are two separate randomized trials with different populations and different comparators, so the two percentages are not a head-to-head result and should not be read as one. Elsewhere on the same page, Found reports a program figure of 12 percent average body weight at one year, based on data from 1,773 users who self-reported weight at least weekly.
Reporting both is more transparent than most of the field manages. The reader’s job is to keep the two apart: a randomized trial measures a drug under protocol, while a self-reported program average measures the people who stayed enrolled and kept logging.
Where the field actually differs
Ro and Hims and Hers both run broad multi-category telehealth businesses with weight programs attached. Noom grew out of behavioral coaching and added prescribing later. WeightWatchers brought a clinical arm alongside its long-standing lifestyle program. Henry Meds built around cash-pay compounded access. Calibrate built its pitch on insurance navigation and intensive coaching. Found sits between the insurance and cash lanes, offering both.
The practical difference is how much arithmetic each publishes before you hand over a card. That matters most at the point where a dose escalates, because a price quoted at a starting strength tells you little about month six. FormBlends is one of the physician-supervised cash-pay providers that lists compounded pricing per strength rather than revealing it after an intake form, which is the single most useful thing a shopper can compare across providers.
One point of confusion worth clearing up: Foundayo is Eli Lilly’s brand name for orforglipron, an oral medication approved in April 2026 under application NDA 220934. It is not a Found product, and Found’s own footer states it is not affiliated with or endorsed by Eli Lilly. The similar names are a coincidence.
A ten-minute switching check
Before moving to any alternative, get five answers in writing. What does the plan cost at the strength you expect to reach, not the starting strength. Which pharmacy fills the prescription. Whether the fee renews on a 28-day cycle or a calendar month. What the named cancellation method is. Whether your state and insurance type are eligible at all.
The named field lines up quickly once those questions are fixed. Ro and Hims and Hers route much of their weight care through insurance or brand fulfillment, LillyDirect sells Eli Lilly’s own drugs at a set cash price, and providers such as HealthRX publish their GLP-1 medications and the supervision around them before an account is created, which is what makes a twelve-month total possible to build in advance. Reading each option on the same five answers, rather than on its headline rate, is the whole exercise.
Compounded medication is not FDA-approved, meaning the agency has not reviewed those specific preparations for safety, effectiveness, or manufacturing quality. That is true of every cash-pay compounded program in this comparison, and it belongs in the value calculation alongside price.
Frequently asked questions
Is the cheapest advertised plan usually the cheapest plan?
Rarely. Advertised rates in this category are typically prepaid annual prices, and the month-to-month equivalent can be substantially higher. Multiply the true recurring charge by the number of billing cycles in a year, then add medication if the plan excludes it. Compare that figure across providers.
Does insurance make a weight program cheaper?
Sometimes, and not automatically. Found’s payment consent states that the subscription fee is a non-covered service that insurance will not pay, and that compounded GLP-1 charges are also non-covered. Insurance may reduce the clinical visit cost while leaving the membership and compounded drug entirely out of pocket.
Are brand and compounded programs comparable on price?
Not directly. A brand plan usually prices only the clinical service, with the drug billed separately at whatever the pharmacy or manufacturer channel charges. A compounded plan often bundles the drug. Comparing a bundled figure against an unbundled one is the most common error shoppers make.
What should decide a switch?
A recurring, documented failure in something that affects treatment: supply gaps, prescriptions that stall between refills, or charges that do not match the published terms. Price alone is a weak reason to move mid-titration, since restarting with a new prescriber often means repeating an escalation you already completed.
Sources
- Tirzepatide Once Weekly for the Treatment of Obesity, SURMOUNT-1. https://pubmed.ncbi.nlm.nih.gov/35658024/
- Once-Weekly Semaglutide in Adults with Overweight or Obesity, STEP 1. https://pubmed.ncbi.nlm.nih.gov/33567185/
- Semaglutide vs Tirzepatide for Weight Loss in Adults With Overweight or Obesity. https://pubmed.ncbi.nlm.nih.gov/38976257/
- Pharmacotherapy for obesity management in adults: 2025 clinical practice guideline update. https://pubmed.ncbi.nlm.nih.gov/40789597/
- FDA, Compounding and the FDA: Questions and Answers. https://www.fda.gov/drugs/human-drug-compounding/compounding-and-fda-questions-and-answers
- DailyMed, Wegovy prescribing information. https://dailymed.nlm.nih.gov/dailymed/search.cfm?labeltype=all&query=WEGOVY
- DailyMed, Zepbound prescribing information. https://dailymed.nlm.nih.gov/dailymed/search.cfm?labeltype=all&query=ZEPBOUND
- CMS, Medicare prescription drug coverage. https://www.cms.gov/medicare/coverage/prescription-drug-coverage
